More articles from Spotlight on Clinical Response

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long

Molecular Cancer Therapeutics Dec 2012, 11 (12) 2704-2708; DOI: 10.1158/1535-7163.MCT-12-0530
Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like Component
Paul K. Paik, Anna M. Varghese, Camelia S. Sima, Andre L. Moreira, Marc Ladanyi, Mark G. Kris, Natasha Rekhtman

Molecular Cancer Therapeutics Nov 2012, 11 (11) 2535-2540; DOI: 10.1158/1535-7163.MCT-12-0163
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock

Molecular Cancer Therapeutics Nov 2012, 11 (11) 2541-2546; DOI: 10.1158/1535-7163.MCT-12-0358
Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification
Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Todd W. Miller, Maria G. Kuba, Ingrid M. Meszoely, Nikhil Wagle, Levi A. Garraway, Carlos L. Arteaga

Molecular Cancer Therapeutics Oct 2012, 11 (10) 2301-2305; DOI: 10.1158/1535-7163.MCT-12-0511
Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer
Geoffrey W. Krystal, Erin Alesi, James L. Tatum

Molecular Cancer Therapeutics Jul 2012, 11 (7) 1385-1388; DOI: 10.1158/1535-7163.MCT-12-0011
Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent
Siqing Fu, Aung Naing, Caroline Fu, Macus Tien Kuo, Razelle Kurzrock

Molecular Cancer Therapeutics Jun 2012, 11 (6) 1221-1225; DOI: 10.1158/1535-7163.MCT-11-0864
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido-Laguna, Elizabeth De Oliveira, Belen Rubio-Viqueira, Steven Strawn, Michael J. Wick, James Martell, David Sidransky

Molecular Cancer Therapeutics Aug 2011, 10 (8) 1311-1316; DOI: 10.1158/1535-7163.MCT-11-0233
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel, N.V. Rajeshkumar, Ignacio Garrido-Laguna, Ana De Jesus-Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison Klein, Daniel Laheru, Ross Donehower, Manuel Hidalgo

Molecular Cancer Therapeutics Jan 2011, 10 (1) 3-8; DOI: 10.1158/1535-7163.MCT-10-0893
Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)
Hazem El-Osta, Filip Janku, Razelle Kurzrock

Molecular Cancer Therapeutics Jun 2010, 9 (6) 1485-1488; DOI: 10.1158/1535-7163.MCT-10-0156
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios S. Bekaii-Saab, Julie M. Roda, Kristan D. Guenterberg, Bhuvanaswari Ramaswamy, Donn C. Young, Amy K. Ferketich, Tammy A. Lamb, Michael R. Grever, Charles L. Shapiro, William E. Carson

Molecular Cancer Therapeutics Nov 2009, 8 (11) 2983-2991; DOI: 10.1158/1535-7163.MCT-09-0820

Main menu

User menu

Search

More articles from Spotlight on Clinical Response

Pages

Articles

Info for

About MCT